Biophysical Mapping of the Adenosine A2A Receptor by Zhukov, Andrei et al.
Published: June 10, 2011
r2011 American Chemical Society 4312 dx.doi.org/10.1021/jm2003798|J. Med. Chem. 2011, 54, 4312–4323
ARTICLE
pubs.acs.org/jmc
Biophysical Mapping of the Adenosine A2A Receptor
Andrei Zhukov, Stephen P. Andrews, James C. Errey, Nathan Robertson, Benjamin Tehan,
Jonathan S. Mason, Fiona H. Marshall, Malcolm Weir, and Miles Congreve*
Heptares Therapeutics Limited, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, U.K.
b S Supporting Information
’INTRODUCTION
G protein-coupled receptors (GPCRs) are one of the most
importantclassesofproteintargetsduetotheircriticalroleincell
signaling in response to hormones, neurotransmitters, and other
metabolites. GPCRs are the site of action for a broad range of
small molecule and biological drugs across many therapeutic
areas. Until recently, the only X-ray structure solved from this
family was that of rhodopsin.
1 Knowledge of how drugs inter-
acted with GPCRs has been limited to models based on
homology with rhodopsin, enhanced by site-directed mutagen-
esis experiments (SDM) with radiochemically labeled ligands.
2,3
In the last 2 3 years, a number of diﬀerent technological break-
throughs have resulted in the structures of ﬁve new GPCRs, all
of which are important drug targets; the β1 and β2 adrenergic
receptors, the adenosine A2A receptor, the CXCR4 chemokine
receptor, and the dopamine D3 receptor.
4 10 Nevertheless obtain-
ing novel GPCR structures in complex with multiple ligands is
still very challenging, with some approaches being limited to
highlypotentantagonistligandsandrequiringspecializedcrystal-
lization techniques in a lipid environment. In addition, crystal-
lographydoesnotprovidedirectinformationregardingtheenergetic
and kinetic contributions of particular interactions. Improved
methods are therefore required to enable structure-based design
approaches to be applied to GPCRs that are complementary
to X-ray crystallography and can be rapidly obtained, thereby
experimentally enhancing in silico design within the short design 
synthesize test cycles essential for drug discovery.
SDM is a technique commonly used in molecular pharmacol-
ogy whereby residues of a protein with a known sequence are
mutated to diﬀering residues so that the eﬀect on binding of the
radioligand being used in the assay can be determined. This
techniqueisextremelypowerfulinidentifyingwhichresidues are
involved in ligand recognition and binding or catalysis.
11 Typi-
cally, mutations that cause signiﬁcant changes in binding aﬃnity
are consistent with the participation of their side chains in direct
ligand interactions, although confounding factors such as “second
shell” eﬀects, changes in solvent structure, and conformational
rearrangements or perturbations may complicate interpretation.
Critically, the requirement for binding measurements using labeled
compounds typically limits studies to one or a few exemplary
ligands, and literature data is consequently often incomplete or
conﬂicting, comprising a sparse matrix of data. What is required,
and is described herein, is a rapid-turnaround direct-binding
method applicable to many ligands and multiple mutations so
that a broad matrix of data can be collected, leading to a self-
consistent and convergent modeling solution for any given
GPCR system.
GPCRs have 7 R-helical membrane spanning domains which
interactwithlipidswithinthemembranebilayer.Inordertocarry
outbiophysicalorstructuralstudies,itisnecessarytotransferthe
protein from the membrane into solution by solubilization with
detergent. This process can often result in unfolding and denatura-
tion of the protein due to its inherent instability. Recently, a new
techniquehasbeendevelopedwhichinvolvestheselectionofmuta-
tions which both increase the thermostability of the receptor as
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ABSTRACT: A new approach to generating information on
ligand receptor interactions within the binding pocket of G
protein-coupled receptors has been developed, called Biophy-
sical Mapping (BPM). Starting from a stabilized receptor
(StaR), minimally engineered for thermostability, additional
single mutations are then added at positions that could be
involvedinsmallmoleculeinteractions.TheStaRandapanelof
binding site mutants are captured onto Biacore chips to enable
characterization of the binding of small molecule ligands using
surfaceplasmon resonance (SPR)measurement.Amatrixofbindingdataforasetofligandsversuseachactivesitemutationisthen
generated, providing speciﬁca ﬃnity and kinetic information (KD, kon, and koﬀ) of receptor ligand interactions. This data set, in
combination with molecular modeling and docking, is used to map the small molecule binding site for each class of compounds.
Takentogether,themanyconstraintsprovidedbythesedataidentifykeyprotein ligandinteractionsandallowtheshapeofthesite
to be reﬁned to produce a high quality three-dimensional picture of ligand binding, thereby facilitating structure based drug design.
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well as driving the receptor toward a particular conformational
state. This technique of conformational thermostabilization has
been demonstrated for the β1-adrenergic,
12 adenosine A2A,
13
neurotensin,
14 and muscarinic acetylcholine receptors.
15 The
resultantstabilizedreceptors,knownasStaRs,
15typicallycontain
4 8 stabilizing mutations. Although these mutations can be
identiﬁed throughout the receptor, they are selected such that
they do not interfere directly with binding to the chosen ligand
class.Inthisstudy,weusedaninverseagonistStaR(fullyinactive
ground state) of the adenosine A2A receptor which has a greatly
increased thermostability compared to that of the wild type
receptor and could therefore be puriﬁed to homogeneity while also
retaining correct folding once immobilized on a chip or bead in
detergent.
15 The StaR (A2A-STAR1, also known as Rant21
13,15)
used here contains 4 mutations spread throughout the receptor
butdistinctfromtheantagonistbindingsite(A54L
2.52,T88A
3.36,
K122A
4.43, and V239A
6.41; superscripts refer to Ballesteros-
Weinsteinnumbering
16).Thepharmacologyhasbeenpreviously
characterized
15andindicatesthatthereceptorhasbeenstabilized
in an inverse agonist conformation.
TheadenosineA2Areceptoriscoexpressedwiththedopamine
D2 receptor on the indirect striatopallidal pathway and acts to
oppose the actions of dopamine agonists. Blockade of the A2A
receptor in rodent and primate models of Parkinson’sd i s e a s e(P D )
withantagonistsalleviatesthemotorsymptomsoftheconditionand
alsohasbeenshowntosuppressL-DOPA-induceddyskinesias.
17
Recently, the clinical agent Preladenant (SCH420814) met its
primaryendpointsinphaseIIclinicaltrialsinmoderatetosevere
PDpatientsandhasprogressedintophaseIII.
18Thisﬁndingand
other encouraging clinical trial results help to validate that antagon-
ismofthisreceptorisausefulapproachtothetreatmentofPD.In
addition,thereisagrowingbodyofliteratureonthepotentialfor
adenosine A2A receptor antagonism to protect from neurode-
generation.
19Aspartofourongoingeﬀortstodevelopadenosine
A2A receptor antagonists for the treatment of PD, both crystal-
lographicand SDMapproaches havebeen afocus ofeﬀort inour
laboratories. With StaRs of the A2A receptor in hand, this system
was chosen to establish a new approach to SDM that we call
biophysical mapping (BPM). Figure 1 illustrates the approach.
Starting from the A2A-StaR1, we envisaged capturing the
receptor onto a SPR chip and establishing that antagonists could
be demonstrated to bind with reproducible potency. Next, a
panel of StaRs with additional modiﬁcations in the binding site
would be generated and each captured on chips in a similar
manner. This panel of receptors would then be cross-screened
with an array of antagonists of varying potencies and from a broad
range of chemical series, generating a matrix of SPR binding and
kinetic data. In this way, it was hoped that a map of the binding
site interactions would be generated that would be useful for
structure-baseddesignapplications.Speciﬁcally,thebindingdata
Figure1. Generalschemeforbiophysicalmappingtechnology.Mutationswithinthepredicted bindingsiteofthe stabilizedreceptor(StaR)ofinterest
are introduced and the proteins expressed as transient transfections. Each receptor, appropriately tagged, is captured directly from the cell lysate onto
Biacore (SPR) chips. Each mutant receptor is then challenged with a panel of antagonists with diﬀerent potencies and from diﬀerent chemistries, and a
matrix ofbindingand kineticdata isgenerated. Molecularmodelingofthe bindingsite,utilizingthese data,reﬁnesboththe proteinstructure andligand
binding interactions for each chemical series.4314 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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wouldbeusedtoguidetheselectionofbestposesfromasetofin
silico docked possibilities for each ligand; docking methods
frequently ﬁnd the correct pose for a ligand, but it can often be
buriedwithinalistof5 10poorlyprioritizedoptions.Inthecase
of the A2A receptor, it would also later be possible to compare
these results with crystallographic information. The following
report details this series of studies on the A2A receptor and the
interpretation of these data.
’RESULTS
ExperimentalDesign/SelectionofMutants.Atthetimethis
work was initiated, there was no structural information available,
and our understanding of ligand binding to the adenosine A2A
receptorwasbasedoninsilicomodelingusinghomologymodels
derived from the stabilized β1-adrenergic receptor X-ray
structure.
7 The models were built with both Modeler
20 and
MOE,
21 with manual adjustments of alignments where neces-
sary. No attempt was made to completely build extra-cellular
loop 2 (ECL2); only the residues between the top of transmem-
brane helix 5(TM5) tothe Cys166 involved ina disulfide bridge
were modeled. Supporting both the model building and, criti-
cally, the docking of ligands was a large set of literature and in-
house SDM data. Adenosine A2A has been the subject of a
number of previous studies to characterize the binding of
radioligands.
22,23 Of particular note, Kim et al. have summarized
SDM results for both adenosine A2A and A1 receptors and the
effects of mutations on the binding of various ligands.
23 By
comparing these data with our model of the binding site, a list of
residues likely to be directly involved in ligand binding was
derived. The residues highlighted by Kim et al. as having a large
effect on antagonist binding were V84
3.32, E151
ECL2, E169
ECL2,
F182
5.43, H250
6.52, N253
6.55, F257
6.59, I274
7.39, and H278
7.43.
Those residuesthoughttobe involved inagonist binding and/or
signalingwere T88
3.36, S277
7.42, andS281
7.46.Residues reported
as also having similar effects on antagonist or agonist binding for
the adenosine A1 receptor were T91
3.36, H251
6.52, N254
6.55,
T277
7.42,andH278
7.43.Oftheseresidues,weconsideredV84
3.32,
F182
5.43, H250
6.52, N253
6.55, I274
7.39, and H278
7.43 to be inside
the A2A antagonist binding pocket. Asn253
6.55 was assigned as
the key H-bonding motif likely to be critical to antagonist
binding. Thr88
3.36 and Ser277
7.42 were proposed to be located
below the antagonist binding site and involved in agonist signaling.
[
3H]ZM241385
24 was the ligand used during the StaR ther-
mostabilization process. During the generation of a StaR, large
numbers of mutations to the receptor are introduced iteratively,
and as well as determining which residues increase the thermal
stabilityofthereceptor,bindingdatawasgeneratedonmutations
thataﬀectthebindingoftheradioligand.Thealaninescanningof
the adenosine A2A receptor identiﬁed a selection of mutants that
resulted in a loss of [
3H]ZM241385 binding. These mutants
provided a proﬁle of the antagonist binding site. Levels of
expression for these mutants were tested by Western blotting
withonlytwomutants,M177A
5.38andN253A
6.55,showingreduced
levels of expression. The mutations L85A
3.33, L167A
ECL2, I66A
2.64,
and N181A
5.42 showed signiﬁcantly reduced [
3H]ZM241385
binding to below 20% of wild type levels, while retaining wild type
levelsofexpression.MutantY271A
7.36bound[
3H]ZM241385at
approximately 40% of wild type levels, while the mutants
N253A
6.55 and H278A
7.43 showed almost a complete loss of
[
3H]ZM241385bindingatsaturatingligandconcentrations.The
two mutants T88A
3.36 and S277A
7.42 proposed to be involved in
agonistsignaling(notedabove)werefoundtobethermostabiliz-
ing as part of the inverse agonist complex and had unaltered
[
3H]ZM241385 binding.
The ﬁnal set of mutations selected for the SPR studies were
L85A
3.33, L167A
ECL2, M177A
5.38, N253A
6.55, Y271A
7.36, I66A
2.64,
N181A
5.42, and S277A
7.42. It was quickly identiﬁed that N253A
6.55
was nonbinding for all compounds attempted; no ligands gave a
signal with this mutated StaR, consistent with previous studies
that suggest this residue has a critical role in ligand binding.
22,23
However, despite evidence that the receptor did give low but
suﬃcient expression for capture on the chip, it cannot absolutely
beruledoutthatnonbindingisinsteadduetotheobservedlower
level of expression.
Interpretation of Data and Generation of Biophysical
Maps. Table 1 summarizes the data collected for each SDM
modified StaR versus a panel of 21 ligands. The log difference in
binding affinity for each binding site mutant is given compared
with the unaltered StaR. Figure 2 shows a representative set of
SPR sensorgrams obtained with one of the compounds,
ZM241385. Figure 3 presents the same data graphically to
visualize the patterns characteristic of a particular compound
series. ZM241385 and SCH420814 are furan containing amino-
heterocyclic analogues, and the latter compound is in clinical
trials for the treatment of PD.
18 Istradefylline (KW6002),
xanthine amine congener (XAC),
25 caffeine, and theophylline
are xanthine derivatives.
26 KW6002
27 has also been studied in
PD clinical trials. Compounds 1a e, 2a b, and 3a h are from
three distinct compound series for which medicinal chemistry
optimization efforts have been undertaken in our laboratories.
The chemical structures of analogues in series 1 and 3 are not
disclosed here and will be the topic of future publications.
However, these data are included to illustrate a number of
aspects of the BPM technology.
First, it is clear that trends in the binding of all ligands
independent of their chemotype or potency can be drawn from
the data set. It is an important ﬁnding that these eﬀects are not
dependent on aﬃnity and that quite weakly active molecules can
be proﬁled and interrogated by this method. The most obvious
feature is that L85A causes an average change in binding aﬃnity
by  1.3 log units relative to that of the unaltered StaR (StaR
background). In comparison, L167A and M177A have on
average only a small eﬀect ( 0.2 log units). Y271A, I66A, and
N181Ahave,onaverage,anintermediateeﬀect( 0.4, 0.7,and
 0.5 log units, respectively). Interestingly, S277A, on average,
causesanincreaseof0.3logunitstoligandbinding.Second,each
chemotype has a distinct ﬁngerprint, supporting the notion that
diﬀerent classes of ligands have, in ﬁne detail, diﬀerent binding
modesinthesite(Figure3).Forexample,compoundsinseries1
havealargerreductioninbindingduetoL85Aandareaﬀectedby
I66A,but other mutations have lessof aneﬀect on thebinding of
these molecules. In contrast, the binding of compounds in series
2i sa ﬀected to a similar extent by the majority of the SDM
changes, suggesting a quite distinct binding mode compared to
that of series 1. In series 3, where the most examples are
presented, there is a fairly consistent trend across the data;
L85A, Y271A, I66A, and N181A all reduce binding, and S277A
causesanincreaseinbinding, especiallywhencomparedtoother
series. These data were very informative in our optimization of
series3,whichwasproposedtobindverydeeplyinthebottomof
the binding cavity, unusually forming interactions inside the
adenosine ribose binding pocket adjacent to Ser277. Finally, in
each series there is a deﬁnite structure activity relationship4315 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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(SAR) related to changes in chemical structure. This additional
information was used to reﬁne the binding of individual analo-
gues and to suggest hypotheses for new compounds to be
synthesized.However,we believethe poweroftheBPMmethod
isintheSARtrendswithinthedataforeachseriesratherthanany
outliers. For example, compounds 3g and 3h seem to be more
adverselyaﬀectedbytheSDMthancloselyrelatedexamples.Itis
likelythatthisissimplyduetotheirveryhighaﬃnity,whereupon
optimal interactions can be readily disrupted, rather than any
signiﬁcant change in binding mode.
In addition to the determination of binding constants given in
Table 1 and discussed above, data for on- and oﬀ-rates (kon and
koﬀ) for each compound against each mutant is generated by the
SPR method. These data are presented in Supporting Informa-
tion, Figure S2. Diﬀerences in binding aﬃnity observed in the
data are most often derived from changes in koﬀ rather than kon.
This is consistent with general observations for other systems.
However, it can be noted that in some cases changes in kon were
important, and in further cases, changes in kon and koﬀ occur but
cancel each other, meaning that overall aﬃnity did not change.
The data provided by the kon and koﬀ values give additional
insight into the energetics of binding of the various compound
series and assist in generating models and hypotheses of the role
of each binding site residue on molecular interactions.
Figure 4 illustrates the chemical structures of the ﬁrst six
molecules in Table 1. In each case, the residues mutated in the
binding site are displayed around the ligand in their relative
orientation according to a homology model we had developed
before any crystal structure data was available. Ile66, Leu85,
Met177, Asn181, and Leu167 are in front of the plane of the
paper (bold), Ser277 and Tyr271 are behind the plane (italic),
and Asn253 is in the plane. N253A
6.55 is assumed to be
nonbinding (NB in the ﬁgure) for all compounds based on
literatureSDMresultsandonbindingexperimentscarriedouton
theﬁrst4compoundsinTable1,allofwhichgavenosignal.The
numbersshownbeloweachresiduelabelarethelogdiﬀerencein
binding aﬃnity relative to the background StaR, and the residue
changes that had the largest eﬀect on each ligand are highlighted
with a black oval, the second largest eﬀect by a dotted circle,
and the third largest eﬀect by a gray box. In cases where there is
a similar eﬀect (either positive or negative) for the ﬁrst, second,
or third tier of binding change, then more than one residue is
highlighted.
Comparison of ZM241385 with SCH420814 indicates that
each ligand interacts with the receptor in a similar way, as judged
by the pattern of binding to the panel of mutant StaRs. In
particular, the ﬁrst and second tier eﬀects are the same with the
mutation of Leu85 and Asn181, respectively. Similarly, both
compounds are aﬀected by changes to Ile66 and Tyr271 to a
similar extent; however, SCH420814 is equally aﬀected by
changes to the other residues in the panel. As noted earlier, very
potent molecules seem to be more generally sensitive to any
change in the binding site, and this is how these third tier eﬀects
could be interpreted for this compound. Alternatively, the larger
tricyclic template and bulky phenylpiperazine substituent might
beresponsibleforthesechanges. Overall,thesedatasupportthat
thefuranmoietiesintheseligandsbindinapocketbelowAsn253
linedbyMet177,Asn181,andLeu85,andweproposedkeyH-bond
contacts with Asn253 to both the furan and the heterocyclic ring
of these molecules. The other residues in the site have smaller or
no eﬀect on the binding of these furan containing analogues,
suggesting no critical interactions with the ligands.
Table 1. SPR Data for a Panel of mutated StaRs versus a Panel of Ligands
a
compound pKi pKD L85A L167A M177A Y271A I66A N181A S277A
ZM241385 8.7 9.3  1.8 0  0.1  0.6  0.6  0.9  0.4
SCH420814 8.8 9.5  2.3  1.0  0.9  0.9  1.0  1.2  0.9
KW6002 6.7 5.9  1.1  0.2  0.3 0  0.2  0.3 0.7
XAC 7.6 7.7  0.3  0.1  0.2  0.5  0.9  0.4 0.3
caﬀeine 5.3 4.6  1.6 0.1 nd 0  1.6 0.6 0.7
theophylline <5 5.5  1.8 0 nd 0.1  0.1  0.4 0
1a 8.5 7.3  1.3  0.1 0.1  0.7  0.7  0.3 0.3
1b 7.6 5.9  2.9  0.1  0.3 0.1  0.5 0.1 0.3
1c 7.5 5.9  0.8 0.1 0 0  0.7  0.3 0.2
1d 6.5 6.1  0.8  0.5 nd  0.6  0.3  0.5 0.1
1e 5.8 5.8  2.8  0.1  0.2  0.3  0.5  0.4 0
2a 7.9 6.0  0.8  0.4 nd  0.5  0.7  0.5  0.6
2b 9.0 7.9  0.9  0.4  0.3  0.1 0.1  0.2  1.0
3a 7.8 6.7  1.1  0.1  0.6  0.8  1.1  1.3 1.0
3b 8.9 8.9  0.8  0.1 0  0.3  0.5  0.5 0.3
3c 8.2 8.5  0.7 0.1 0  0.3  0.4  0.7 0.8
3d 8.1 8.2  0.8 0.1 0.1  0.3  0.3  0.6 0.9
3e 7.9 8.2  0.8 0.1 nd  0.2  0.8 0.1 1.2
3f 8.0 8.5  0.9 0.3 0.5  0.1  0.7  0.6 1.4
3g 8.6 9.3  1.1  1.4  0.8  1.4  1.5  1.0 0.7
3h 8.6 9.2  1.1  0.7  0.8  1.1  1.2  0.6 0.8
aThe SPR data for each mutated StaR is given as a log diﬀerence compared with the unaltered StaR background (pKD). The pKi value versus the wild
type receptor is also given in the Table for each compound, as determined in a radioligand binding assay (using [
3H]-ZM241385) for comparison. In
most cases, the pKi and pKD values are very similar, and diﬀerences are likely due to the low solubility of certain ligands which, we have observed, can
cause diﬀerences between the assays. nd = not determined (due to low signal). Errors in pKD diﬀerence values are typically (0.1.4316 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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The four xanthine analogues display a more complex pattern
ofinteractionswithinthebindingsite.Carefulexaminationofthe
data seems to support a subtly diﬀerent binding mode for the
xanthine moiety of caﬀeine and of KW6002 as compared with
that oftheophylline andXAC. Caﬀeine hasamethyl groupon its
imidazoleringthatwouldpreventanyH-bondingwithAsn253to
that ring, while theophylline lacks this substituent, allowing for
thispossibility.Acomparisonofcaﬀeinewiththeophyllineshows
eﬀectsonaﬃnityintheﬁrstandsecondbindingtiertoLeu85and
Asn181,suggestingtheligandssitrelativelydeepinthebottomof
thereceptor,adjacenttoAsn253.However,caﬀeineisaﬀectedby
changes to Ser277 (þ0.7 log) and Ile66 ( 1.6 log), while
theophyllineshowsnosucheﬀect.Theophyllinethereforeseems
to be forming H-bonds to Asn253 with a positioning in the site
close toLeu85andAsn181,withnofurtherkeydirector indirect
interactionswiththeotherresiduesstudied.Caﬀeine,incontrast,
appears to sit further from Asn253, presumably forming a single
H-bond to one carbonyl group and is apparently positioned
closer to S277 (þ0.7 log) and Ile66 ( 1.6 log). Furthermore,
comparison of caﬀeine with KW6002 (which is also N-methy-
lated on the imidazole ring) shows a similar pattern of interactions
with Leu85 and Ser277. This indicates a similar overall binding
mode of the core fragment, but diﬀerences in the eﬀects of
Asn181 ( 0.3 log) and Ile66 ( 0.2 log), suggesting, in ﬁne
detail, a shift in the vector of the xanthine moiety or, perhaps
morelikely,aneﬀectoftheethyl(versusmethyl)substituentson
the heterocyclic core. Finally, a comparison of theophylline with
XACsuggeststhatXACformsanumberofnewinteractionswith
the receptor, but the data again overall suggests the molecule sits
adjacent to Asn253 and accesses the residues lining the bottom
of the pocket. The larger propyl substituents (as compared with
methyl groups on theophylline) may account for the interaction
with Ile66 ( 0.9 log), which is diminished in the smaller
derivative. The amide group in XAC appears to be positioned
close to Tyr271 ( 0.5 log) compared with the styryl group of
KW6002whichappearstoformnointeractionswiththeresidues
on that face of the receptor (Tyr271, Leu167, and Ile66), again
suggesting a subtly diﬀerent vector in the presentation of these
two molecules to the key H-bonding Asn253 residue.
Modeling of the Binding Modes of ZM241385 and XAC.
Figure 5 illustrates the structures of ZM241385 and XAC bound
to an adenosine A2A homology model optimized using the BPM
Figure 2. Kinetics of ZM241385 binding to A2A StaR and seven binding site mutants as analyzed by SPR. The adenosine A2A StaR proteins were
immobilized onNTA chips onaBiacore T200instrument andaseries ofligandconcentrations (5 80nM) injected in thesingle cycleformat at10 C.
The data were ﬁtted to a 1:1 interaction model to generate KD values, and the data are presented in Table 1 and Figure 3.4317 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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data detailed above. Homology models were constructed from
the β1 adrenoceptor crystal structure in the protein data bank
(PDB; 2VT4),
7 with manual readjustmentand refinement based
on known conserved GPCR motifs and SDM data (published
and in-house, as discussed earlier). In Figure 5, the first, second,
andthirdtierBPMeffectsdescribedaboveandshowninFigure4
arecolored,alongwithAsn253,whichisessentialforthebinding
of ligands to the receptor. The two ligands share a significant
portion of the A2A binding pocket in both position and interac-
tions with residues lining the pocket. Both have π π interac-
tions with their central aromatic cores and Phe168 from ECL2,
hydrophobic contacts with Leu249 and Met270 (not shown in
the figure), and hydrogen bonding contact with Asn253. The
interactions at the bottom of the pocket seen for ZM241385 are
highlighted in Figure 5 as the most significant, designated as first
and second tiers in the BPM experiments. Most important of
theseisthealmosttwologdropinactivityfortheL85Amutation.
The Leu85 forms one side of the hydrophobic cavity into which
the furan ring, known to be essential for ligand binding, sits. The
furan alsoforms akey hydrogen bondwithAsn253.Lastly inthis
region, the Asn181 forms part of the pocket where the furan ring
bindsandthushasaneffectwhenmutatedtoAla,asshownbythe
BPM in Table 1 and Figure 4.
At the entrance to the binding site, the model has an open
arrangement that allows stacking of the phenolic substituent of
the ligand with Tyr271 in a cleft at the extracellular ends of
helices 1, 2, and 7. This allows the second tier eﬀect with Tyr271
to be accounted for in the binding pose with a sensible ligand
conformation. This ﬂexible part of the ligand was best accom-
modatedbythesolutionpresentedhere,andwerationalizedthat
the pose was reasonable on the basis of the BPM data and
previously published SDM and SAR data that suggested the
importance of the substitution pattern of groups on the phenyl
ring for potency and selectivity, suggestive of engagement of the
side chain in a subpocket within the binding site.
22,23,28,29
XACandZM241385areoverallproposedtositsimilarlyinthe
model, but there are some signiﬁcant diﬀerences that aﬀect the
way they are positioned within the model of the A2A binding
cavity. The most signiﬁcant diﬀerence between the two inverse
agonists is the interaction proposed for XAC with Ile66. One of
Figure 3. Eﬀect of active site mutations on binding aﬃnities of compounds representing ﬁve diﬀerent chemical series. These data are a graphical
representation ofthedata presented inTable1and showhowdiﬀerentcompound series havediﬀerentﬁngerprintswhichmaptheir interactionswithin
thereceptorbindingsite.On-andoﬀ-ratesofligandsbindingtothetargetreceptorswerealsomeasuredandindicatedthatSDMchangestypicallyaﬀect
the oﬀ-rate rather than the on-rate (see Supporting Information).4318 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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the propyl chains traverses the width of the binding site where it
makes a signiﬁcant hydrophobic interaction within a lipophilic
cavity in the binding site deﬁned by Ile66, Ala63, Val84, and
Ala81. ZM241385 does not access this lipophilic cavity, and
mutationofIle66hasasmalleﬀectonitsbinding.Thissigniﬁcant
hydrophobic interaction with Ile66 for XAC is therefore con-
sistent with the marked decrease on binding seen with the
mutation of Ile66 to Ala (reduced by almost 1 log unit). This
major reduction in XAC’sa ﬃnity with the Ile66 to Ala mutation
is designated as ﬁrst tier in Figure 5. It was very interesting to us
that the BPM highlighted this residue because all high scoring
dockingposesdidnotpredictanyinteractionwiththisresidue.In
order to recapitulate the interactions the ligand is predicted to
make from the biophysical map, it was necessary to rotate the
carboxamide of the Asn253 in the model to better present the
NH2 donor to the C6 carbonyl of the xanthine. This illustrates
that docking of xanthine ligands such as XAC was very challen-
ging without the additional information provided by the BPM
experiments. This interaction with Ile66 may actually be as a
result of the steric bulk present on the ligand from the second
propyl substituent that serves to cause a rotation of the scaﬀold
relative to ZM241385. This has the eﬀect that XAC has only one
H-bonding interaction with Asn253 and forms subtly diﬀerent
interactions with the residues that form the bottom of the
binding site (Ser277, Leu85, Asn181, and Met177) compared
withZM241385.TheseinteractionsforXACwiththebaseofthe
bindingsitearethird tiereﬀectspossiblybecause oftheﬂexibility
of this lipophilic propyl chain accessing this part of the binding
site, allowing the ligand to adapt to SDM changes introduced in
this region. In ﬁnalizing the proposed binding mode, we took
into account that the S277A mutantactuallyincreases binding of
the ligand (shown as green in the ﬁgure), consistent with
placement of the hydrophobic side chain in this region. Finally,
whenexaminingtheBPMbindingmodeofXAC,atthetopofthe
binding site the Tyr271 chi1 angle is in a trans conformation in
the model where it is able to make a weak π π stacking
arrangement with the phenyl ring of XAC. This is consistent
with the moderate (2nd tier) eﬀect seen on the binding of XAC
to the Y271A mutant with a drop of half a log in binding.
Interestingly, inarecent paperbyCheng etal.abindingmode
for xanthines in adenosine A2A is proposed that has some
similarity to our BPM guided pose.
30 Cheng et al. also conclude
Figure 4. Representative BPM interpretation. Chemical structures of ZM241385, SCH420814, KW6002, caﬀeine, XAC, and theophylline annotated
with the BPM data for each ligand in a cartoon representation based on a homology model of the A2A receptor. The residues shown were in each case
mutated to Ala, and beneath the label is the log diﬀerence in binding for that compound. Residue labels are positioned to represent their position in the
bindingsite and relative to the ligand.Residues labeledin boldarein frontofthe plane, initalics are behindthe plane,and innormal fontinthe planeo f
the ligand. Asn253 is included in each case, and NB = nonbinding (see text). ND = not determined. The numbers below each residue label are the log
diﬀerence in binding relative to the StaR background. The residue changes that had the largest eﬀect on each ligand are highlighted with a black oval,
secondlargesteﬀectbyadottedcircle,andthirdlargesteﬀectbyagraybox.Incaseswherethereisasimilareﬀect(eitherpositiveornegative)forthe1st,
2nd, or 3rd tier of binding change, then more than one residue is highlighted.4319 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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that the xanthine ligands only form one H-bonding interaction
with the Asn253 and that there is a signiﬁcant interaction with
Tyr271. However, as the xanthine ligands are docked into a
published adenosine A2A crystal structure (PDB: 3EML) in
whichTyr271isinthegauchenegativeconformationthebinding
mode suggested here is not possible.
30 This is because the top of
the binding site is partially occluded in the position occupied by
the substituted phenyl group. However, the binding pose of
xanthines proposed by Cheng et al. in A2B is very similar to the
results presented here because Y271 (A2A) is actually N273
(A2B),andthus,thereisnoresidueobstructingthisportionofthe
binding site.
ThelaterpublicationofanadenosineA2Areceptorstructurein
complex with ZM241385 allowed us to make a comparison of
our biophysical map of this ligand with an X-ray crystal data set.
8
The diﬀerence between the backbone rmsd of the homology
model and the crystal structure is 2.78 Å over all residues
included in the model. Most binding site residues within the
TM region showed a high degree of similarity, as was also found
byIvanovetal.inanotherrecentcomparisonofamodelwiththis
X-ray data.
31 Within the binding site, there are small diﬀerences
comparing the residues from the top of TM2, notably Ile66,
being somewhat further away from Asn253 in our homology
model compared to the crystal structure, perhaps helping to
explaintheimportanceofthisresidue(Table1).Diﬀerences,not
surprisingly,werealsoseeninresiduesemanating fromtheloops
which are notoriously diﬃcult to model, notably in the exact
position of Phe168 on ECL2, which forms stacking interactions
with the ligand in the site.
11,32 However, the most important
diﬀerence aﬀecting the binding pose of the ligand ZM241385
between our model and the crystal structure (PDB: 3EML) was
the chi1 angle of Tyr271. In the 3EML crystal structure, chi1 of
Tyr271 is in a gauche negative rotameric state, compared to
the trans conformation in our model, which causes the ﬂexible
phenolic portion of ZM241385 to sit in quite diﬀerent positions
comparing the two binding poses. This gauche negative
rotameric state of Tyr271 chi1 serves to eﬀectively block the
channel between helices 2 and 7 where we proposed the ﬂexible
phenolic portion of ZM241385 might bind. While we also
obtained docking poses that did place this portion of
ZM241385 in a similar place to that seen for 3EML, these poses
did not satisfy the BPM data that are presented here and thus
were discarded. The BPM guided docking of ZM241385, how-
ever,didshowaverysimilarplacementofthecentralcorewithan
approximately 10 clockwise rotation of our BPM guided pose
relativetothe3EMLmodel,resultinginaheavyatomrmsdofthe
central core of 1.78 Å. The most signiﬁcant region of displace-
ment was where the ﬂexible phenolic portion joins onto the
central core. Importantly, the B factor (or temperature factor, a
crystallographic measure of disorder) of the ﬂexible phenol
group in the A2A crystal structure is high (>100 Å2) compared
to the rest of the ligand (∼50), suggesting the position of this
substituent should be interpreted with caution and may adopt
morethanoneconformation.
33Inourongoingresearch,wewere
subsequentlyabletosolveacrystalstructureofanadenosineA2A-
StaR with ZM241385 bound. Interestingly, this structure has
Tyr271 positioned in a trans arrangement, diﬀerent from its
position in 3EML, that opens the binding cleft between helices 2
and 7 and is in a position similar to that in the homology model
described in this article.
34 In this structure, the ﬂexible phenolic
portionofZM241385doesindeedbindwithinthiscleftbetween
helices 2 and 7, consistent with the results from the BPM study
presented here and also with the SAR seen for this well explored
series of compounds.
28,35
In summary, the studies presented here show how a selection
of binding site mutants can be made and SPR binding data
subsequently generated for each mutant receptor against a panel
of ligands with a broad range of potency and diverse chemistry.
Interpretation of the binding modes of each chemical series and
individual molecules within each series can be made using in
silicodockingagainstahomologymodel,itselfreﬁnedandimproved
using the BPM data. Comparison of the binding modes suggested
Figure5. DockedstructuresofZM241385(left)andXAC(right)inanadenosineA2Areceptorhomologymodel.Asn253iscoloredredasSDMofthis
residuepreventsbindingoftheligands(seetext).The1st,2nd,and3rdtiereﬀectsofmutationswithinthebindingsitearecoloredaccordingtothekeyin
the ﬁgure (also see text) and relate to those residues indicated in Figure 4 from the BPM experiments.4320 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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from the BPM matrix with subsequently solved receptor ligand
X-ray structures demonstrates the value of the approach, and the
BPM data additionally serves to improve our understanding of
the ligand interactions seen in the crystal structures.
’DISCUSSION
The BPM approach described here is an important link
between computational (in silico) docking and X-ray structures
of ligands bound to their receptor sites. In the absence of any
X-ray crystal structure data, the information provided by the
BPM of known ligands can be used to validate and improve
homology models (including orientation of key binding site
residues) and the way they are used to dock and score com-
pounds. This potentially improves the ability of a given model to
identify new ligands, such as via virtual screening of large
databases of existing compounds, and also to predict the binding
orientation of known ligands. Generating BPM data on a ligand
of interest provides higher conﬁdence in the binding pose/
orientation predictions made by in silico docking and can lead
to predictions of binding modes for compounds that are very
closetotheexperimentalbindingmodeobservedwhentheX-ray
crystal structure is ultimately obtained. This is not limited to ﬁne
tuning of known binding modes but can be used to correctly
predict novel binding modes. For example, the compounds in
series 3 (Table 1) were identiﬁed by virtual screening of our
homologymodeloftheadenosineA2Areceptor, carefullyreﬁned
and validated using SDM and BPM data. Furthermore, the BPM
data and binding mode predictions were very useful to the
project team, enabling the rapid optimization of the series and
allowing identiﬁcation of advanced lead molecules that have
excellentdrug-likepropertiesandhaveledtotheidentiﬁcationof
a preclinical candidate for the treatment of PD. An important
validationoftheBPMmethodcomesfromlatercrystalstructures
of members of this series. The structures are highly consistent
withtheBPMdatapresentedinthisarticleandthebindingmode
derivedfrom these datathatwas being used during the optimiza-
tion of the compound series (unpublished results).
The choice of which residues are to be mutated during the
BPM screening is a critical part of the process that is done by
careful analysis of the 3D structure or homology model of the
receptor together with potential ligand docking poses and any
available SDM data. Mutations to cover all plausible binding
modesarethenconsidered,modulatingthesizeorpolarityofthe
residue in a way that is likely to give the most informative data.
Therearenaturallylimitationstotheapproach,mostimportantly
that allosteric binding sites may not be predictable at the outset,
such that no mutations are made to probe binding at that site.
However,thelackofbindingenergychangesbymutationstothe
orthosteric binding site residues would at least inform that
binding was occurring at an alternative site. An additional
consideration is that if a mutation ablates binding for all
compoundsstudied,thenexpressionandproteinimmobilization
on to the SPR chip need to be carefully examined. In the
experiments presented here, all mutations in the panel were to
alanine.InourongoingBPMstudiesforotherreceptors,wenow
makemultiplemutationsforeachkeyresiduewithinthesitesuch
that we can identify mutations that aﬀect but do not completely
block ligand binding, aiding the interpretation of results.
An exciting approach to ﬁnding hits for targets of interest
is fragment-based drug discovery (FBDD).
36 In this approach,
smaller compounds (fragments) are typically screened by a
biophysical method that is able to identify small (molecular
weight generally less than 250 300 Da), low aﬃnity (high
micromolar to low millimolar) compounds that are ligand
eﬃcient.
37Chemicalelaborationofthesefragmentsthenenables
the identiﬁcation of compounds with good physicochemical
properties and target selectivity. The important ﬁrst step is to
screen a relatively small library of fragment-size compounds and
toidentifycompoundswithagood(energeticallyfavorable)ﬁtto
the binding site, and this can be done, for example, by SPR or
NMR based screening using StaR proteins.
38 This is in contrast
to high throughput screening (HTS) whereby much larger hits
are often obtained, with compounds that can be making sub-
optimal interactions with the protein. Many interesting new
binding motifs can be rapidly identiﬁed by the fragment-based
approach. The utility of the BPM technology is thus potentially
not limited to lead-sized potent molecules but due to the ability
oftheSPRscreeningapproachtodetectveryweakbinderscanbe
used to provide structure-based design in the critical fragment to
hit/lead stage. The BPM data enables characterization of where
fragments are binding, distinguishing between orthosteric or
other (allosteric) site binders, being used to screen panels of
analogues in a SAR by catalogue approach or by guiding the
synthesis of derivatives. This capability is very important to
enable structure-based design for fragment hits before an X-ray
structure can be obtained, as computational docking approaches
are poor at providing high conﬁdence poses for small com-
pounds, generally giving several plausible possibilities. The data
for caﬀeine and theophylline described in this article are exam-
ples of fragments binding to a GPCR, and the BPM method
allowed the binding modes of these molecules to be predicted in
a mode largely consistent with medium resolution X-ray struc-
tures of these compounds and of the larger analogue, XAC, that
have subsequently been solved in our laboratories.
34 One con-
sideration is that in some cases a small fragment might still bind
with similar aﬃnity to a mutant receptor due to a signiﬁcant
compensating change in its binding mode; however, this situa-
tion would be expected to be uncommon.
In conclusion, the matrix of direct binding information
provided by the BPM approach provides early access to quality
experimental data that allows better prediction of correct ligand
binding poses and quantiﬁes the eﬀects on binding of changing
residues around the binding site. Structure-based design for a
receptor target is thus greatly enabled by having a more accurate
binding pose, using experimental information. Additionally, an
understandingoftherelativeimportanceofdiﬀerentinteractions
with binding site residues, given by the BPM approach, can be
used to guide design in a SAR program. Coupled with the advances
in homology modeling made possible by new GPCR structures
becomingavailable,enhancedbyimprovedforceﬁelds(takingmore
account of polarization, etc.), increased desktop computational
power, and new in silico methods for improving docking predic-
tions,the BPM method has greatpotentialtosupportvirtualand
fragment hit identiﬁcation campaigns and empower SBDD for
lead optimization. Without the BPM data on our adenosine A2A
antagonist lead compounds, it would not have been possible to
use SBDD methods with conﬁdence until much later in the
project,whenX-raystructures withourligandsbecameavailable.
’EXPERIMENTAL SECTION
Materials. The A2AR receptor StaR used as the background is a
thermostabilized mutant previously known as RANT21,
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includes the following thermostabilized mutations: A54L
2.52, T88A
3.36,
K122A
4.43, and V239A
6.41 and was used as the background for the
additional site-directed mutagenesis. [
3H]-ZM241385 was supplied by
American Radiochemicals (USA). Ni-nitroltriacetic acid (Ni-NTA)
agarose was obtained from Qiagen (UK). All detergents were from
Anatrace, Affymetrix (USA). Transient transfection reagent Genejuice
was supplied by Merck Biosciences (USA).
Mutagenesis. Mutants were generated by PCR using the KOD
PCR system (Merck Biosciences, USA) and the expression plasmid as
template. PCRs were transformed into DH5R ultracompetent cells
prepared according to the Inoue method, and individual clones were
fully sequenced to check that only the desired mutation was present.
Different mutations were combined by PCR as described above and
sequenced to check plasmid integrity and desired mutations.
Protein Expression. HEK-293T mammalian cells were used to
expressadenosineA2Aanditsmutants.Briefly,HEK293Tcellculturesin
10 cm cell culture plates at 50% confluency (4.5   10
6 cells) were
transiently transfected with 6 μg of plasmid and left to grow in DMEM
(Lonza) supplemented with 10% fetal bovine serum (Sigma) at 37 C
and 5% CO2. Cells were harvested 40 h later by dissociation into
phosphate buffersaline(Sigma) andpelletedat600gfor5min(aliquots
of 2 mL), and stored at  20 C.
Radioligand Binding. Competition binding studies were incu-
batedinbuffercontaining50mMTris-HCl(pH7.4)inafinalvolumeof
0.25 mL with 10   0.5 log unit dilutions of test compounds and a final
[
3H]-ZM241385 concentration of 0.5 nM. After incubation for 90 min
at room temperature, assays were terminated by rapid filtration through
96-well GF/B UniFilter plates presoaked with 0.1% PEI followed by
washingwith5 0.25mLofddH2O.Platesweredried,50μLofUltima
Gold-F added per well, and bound ligand measured using a Packard
Microbetacounter.Datawerenormalizedas%specificbindingfollowed
by fitting according to a four parameter logistic fit to determine pIC50;
this was converted to pKi using the KD value generated from saturation
binding studies.
Determination of Protein Concentration. The protein con-
centration was determined using a detergent-compatible Bradford assay
(BioRad).
Chemical Compounds. SCH420814 and KW6002 were synthe-
sized by Jubilant Chemsys Ltd. (India), according to published proce-
dures. Their purities were determined by LCMS and were found to be
>95%.
1HNMRspectraofthesecompoundswererecordedat400MHzona
Jeol instrument. Chemical shift values are expressed in parts per million,
i.e., δ values. The following abbreviations are used for the multiplicities
of the NMR signals: s = singlet, d = doublet, t = triplet, q = quartet,
dd = doublet of doublets, and m = multiplet. Coupling constants are
listed as J values, measured in Hz.
LCMSanalysisofthesecompoundswasperformedbyJubilantChemsys
Ltd.underthefollowingconditions:column,AquityBEHC-18,1.7μm,
2.1   100 mm; column temperature = 30 C;and ﬂow rate = 0.3 mL/min.
Gradient [time (min3s)/solvent B in A (%)]: 0.00/90, 1.00/90, 2.00/
85, 4.30/45, 6.00/10, 8.00/10, 9.0/10, 10.00/10 (solvent A = acetoni-
trile; solvent B = 5 mM aqueous ammonium acetate).
KW6002
39.(8-[(E)-2-(3,4-Dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-
3,7-dihydro-1H-purine-2,6-dione)
1H NMR (400 MHz, DMSO-d6) δ:
7.58 (d, J = 15.80 Hz, 1H), 7.39 (d, J = 1.83 Hz, 1H), 7.27 (dd, J = 1.72,
8.36 Hz,1H),7.18 (d, J=15.80 Hz, 1H),6.95 (d,J=8.47 Hz,1H),4.03
(q,J=7.10Hz,2H),3.99(s,3H),3.88(q,J=7.10Hz,2H),3.81(s,3H),
3.76 (s, 3H), 1.22 (t, J = 7.10 Hz, 3H), 1.09 (t, J = 6.98 Hz, 3H). LCMS
5.95 min, 97.92% purity (UV); m/z 385.23 (ESþ).
SCH420814
40. (2-(Furan-2-yl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]-
piperazin-1-yl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-
5-amine)
1HNMR(400MHz,DMSO-d6)δ:8.09-8.16(m,1H),7.99-
8.07 (broad s, 2H), 7.86 - 7.94 (m, 1H), 7.16 - 7.23 (m, 1H), 6.78 - 6.83
(m, 2H), 6.74 - 6.78 (m, 2H), 6.67 - 6.73 (m, 1H), 4.31 - 4.43 (m, 2H),
3.89-3.99(m, 2H), 3.53- 3.62(m, 2H), 3.25 (s, 3H), 2.87- 2.98(m, 4H),
2.76-2.83(m,2H),2.52-2.60(m,4H).LCMS5.13min,95.04%purity
(UV); m/z 504.45 (ESþ).
ZM241385 (4-(2-(7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-
[1,3,5]triazin-5-ylamino)ethyl)phenol; Tocris Cookson), XAC (N-(2-
aminoethyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-
8-yl)phenoxy]-acetamide; Sigma Aldrich), caﬀeine (Sigma Aldrich) and
theophylline (Sigma Aldrich) are commercially available.
LCMS analysis of these commercial samples was performed at Heptares
under the following conditions: instrument, Waters Alliance 2795, Waters
2996PDAdetector,MicromassZQ.Column:PhenomenexGemini-NX
C-18, 3 μm, 2.0   30 mm. Gradient [time (min)/solvent B in A (%)]:
0.00/2, 0.10/2, 8.40/95, 9.40/95, 9.50/2, 10.00/2 (solvent A = 1.58 g
ammonium formate in 2.5 L of water þ 2.7 mL of 28% aqueous ammonia
solution; solvent B = 2.5 L of acetonitrile þ132 mL of solvent A þ
2.7 mLof28%aqueousammoniasolution). Injectionvolume,5μL;UV
detection, 230 to 400 nM; column temperature, 45 C; and ﬂow rate =
1.5 mL/min. The LCMS purity was found to be >95% in all cases.
LCMS results for commercial samples (retention time, UV purity,
observed ion in ESþ mode): ZM241385 (2.42 min, >95%, m/z 336.3),
XAC (1.83 min, >95%, m/z429.3), caﬀeine (1.07 min, >95%, m/z194.9),
and theophylline (0.13 min, >95%, m/z 181.0).
SPR Analysis. SPR analysis was carried out at 10 C on Biacore
T100 and Biacore T200 instruments using sensor chip NTA
(GE Healthcare). PBSwas used as runningbuffer with 0.1% dodecylmalto-
side, 0.05 mM EDTA, and 5% DMSO, pH 7.4. To solubilize the
adenosine A2A receptor from the membranes of HEK-293T cells, the
pelleted membranes were mixed with an equal volume of ice-cold
40 mM Tris-HCl and 3% decylmaltoside, pH 7.4, and homogenized
in a Dounce homogenizer. The mixture was centrifuged (13200 rpm, 5
min)andthepelletdiscarded. Thesupernatant wassupplied with5mM
imidazole and injected over a nickel-loaded NTA chip (1 μL/min, 10
min) to capture the His-tagged receptor. The capture levels of the wild
typeandmutantreceptorsvariedintherangeof4000 10000resonance
units (RU). To assay the receptor ligands for the affinity and kinetics of
their interactionwiththereceptor,2-folddilutionseries(fiveconcentra-
tions) wereprepared andinjectedineither multi-or single-cycleformat.
The actual concentrations as well as contact and dissociation times varied
betweentheligandsdependingonthekineticsandaffinityofinteraction.
The data were generally fitted to the 1:1 interaction model. Some low-
affinity ligands, which needed to be assayed at higher concentrations,
exhibited a distinct secondary interaction component. This secondary
interaction was characterized by low affinity and was often super-
stoichiometric. In cases with significant contribution of the secondary
component, the data were fitted to the two-site interaction model, and
onlytheprimary,highaffinity,componentwastakenintoconsideration.
Binding constants were compared with affinities measured by radioligand
binding (the above method and Table 1), and compounds that per-
formed poorly due to solubility issues were discarded from the screen.
Computational Chemistry. Homology models were constructed
from the avian β1 adrenergic GPCR crystal structure bound to cyano-
pindolol (PDB: 2VT4).
7,41 Owing to the relatively low percentage
identity between the two proteins (25% overall, less than 20% around
the ligand binding site), two initial homology models of the adenosine
A2A receptor were generated, using different methods. This provided a
meanstoassessconsistencyinthealignments,thevariabilitywithinthebuilt
structures,andwhichregionsofthemodelshadlowerconfidenceassociated
withthem.OnemodelwasconstructedusingModeler,
20whiletheother
was constructed using MOE,
21 with manual readjustment of the
clustalW alignment where necessary.
42 The alignment in each case
was checked to ensure consistency with known GPCR conserved
motifs
43 and particularly the conserved disulfide bond, common to
family A GPCRs, which is located between the top of helix 3 and the4322 dx.doi.org/10.1021/jm2003798 |J. Med. Chem. 2011, 54, 4312–4323
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extracellular loop 2. The model generated via MOE was selected for
further optimization as the Phe168 residue, implicated in antagonist
binding, was in closer proximity to the other residues highlighted from
literature SDM.
Initial validation and improvement of the homology models was
conducted with ZM241385, due to the wealth of SAR for this series and
the amount of SDM data available for the ligand at the adenosine A2A
receptor. The induced-ﬁt docking protocol was used within Maestro
with an autogenerated box size around the residues highlighted by in-
house and external SDM as having a large eﬀect on antagonist binding,
namely, I66
2.64, V84
3.32, L85
3.33, E151
ECL2, L167
ECL2, E169
ECL2,
N181
5.42, F182
5.43, H250
6.52, N253
6.55, F257
6.59, Y271
7.36, I274
7.39,
and H278
7.43. The resultant docking solutions in combination with
the binding data from the thermostabilization experiments were then
used to select the in-house round of mutants for our biophysical mapping
experiments. These mutations were chosen so as to conﬁrm or rule out
diﬀering possible binding orientations within the A2A receptor.
The ﬁnal docking experiments were guided by ligand SAR and our
iterative process of assessing SDM and then designing our own BPM
mutants to conﬁrm or rule out possible binding modes. The protein
preparation anddocking experimentsweredonewithintheSchrodinger
Maestro package.
44Thegridgenerationnecessary fordockingwas done
within Glide. The residues highlighted in SDM experiments (in-house
and external) were used to deﬁne the cavity of the grid; however, no
constraints were added in the grid generation to ensure that subsequent
dockings were not biased in any way. Glide XP docking was carried out
on all of the ligands in question with 10 poses per ligand being stored.
The poses were then assessed against the biophysical mapping data
(Table 1) and the best solution identiﬁed.
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